In advanced therapies, outcomes are rarely determined at the point of delivery, they are set much earlier, by decisions teams don’t always recognize. At Orchestra
Execution as a Design Problem in Advanced Therapies Advanced therapies are being shaped by constraints that sit outside the lab. Scientific progress continues, but outcomes
Orchestra Life Sciences’ Year-End Perspectives The life sciences sector entered 2025 with considerable momentum and concluded the year having experienced meaningful scientific, regulatory, and operational
Advanced therapies are rapidly evolving, but talent development has not kept pace. Across the US, companies struggle to hire and retain operators, quality specialists, and
Despite the perceived macroeconomic slowdown, major pharma continues to invest heavily in next-generation gene therapy platforms. Capital is flowing toward programs that show operational growth,
Every industry has its inflection point, for biotech, that moment is unfolding in Philadelphia. Anchored by University City’s innovation corridor, Philadelphia has evolved from an
Author: Zach Lewis, Director, Regulatory and Compliance In today’s race to bring advanced therapies to patients, one hurdle continues to plague the industry: Chemistry, Manufacturing,
Biotech financing is beginning to rebound, but not across the board. According to June 2025 data, public biotech fundraising surpassed private for the first time
Quality infrastructure is an essential foundation for success in radiopharmaceutical and cell & gene therapy manufacturing. To meet modern industry expectations, companies must transition away
Radiopharmaceuticals Are Changing the Game Radiopharmaceuticals are at the forefront of modern medicine and are changing the way we fight complex cancers. These novel compounds